NCT07168018View on ClinicalTrials.gov

Safety and Immunogenicity of Coadministration of the Candidate Rabies Vaccine ChAdOx2 RabG and Licensed Vaccine

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Rabies
Interventions
BIOLOGICAL

Coadministration of ChAdOx2 RabG and licensed inactivated rabies vaccine (IRV)

A single visit of coadministration of 5×10\^10 vp ChAdOx2 RabG (2 site IM) and licensed IRV (2 site IM).

BIOLOGICAL

Inactivated Rabies Vaccine (IRV)

A World Health Organization (WHO) prequalified IRV at two anatomical sites (2 site ID) on days 0, 3 and 7.

Trial Locations (1)

Unknown

Ifakara Health Institute, Bagamoyo

All Listed Sponsors
lead

University of Oxford

OTHER